Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008741

SCHEMBL1008741

SCHEMBL1008741

COc1ccccc1Oc1cnn(C(CC2CCCC2)C(=O)O)c(=O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 4/20 0.39
▸ LPAR5 Q9H1C0 4/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ CCR8 P51685 2/20 0.37
▸ PDE4A P27815 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ PDE4C Q08493 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ TNF P01375 1/20 0.36
▸ LITAF Q99732 1/20 0.36
▸ METAP2 P50579 1/20 0.35
▸ METAP1 P53582 1/20 0.35
▸ F11 P03951 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ HCRTR1 O43613 1/20 0.35
▸ HCRTR2 O43614 1/20 0.35
▸ APLNR P35414 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009403 0.90 LPAR1 (0.41) LPAR1LPAR5KMT2AHPGDMETAP2
SCHEMBL1008604 0.88 METAP2 (0.36) METAP2METAP1F11
SCHEMBL1008265 0.88 FFAR1 (0.40) KMT2AALDH1A1METAP2METAP1TDP1
SCHEMBL1007288 0.88 LPAR1 (0.41) LPAR1LPAR5METAP2METAP1
SCHEMBL1008619 0.87 FFAR1 (0.38) TNFLITAFMETAP2METAP1F11
SCHEMBL1009332 0.87 FFAR1 (0.43) KMT2AALDH1A1METAP2METAP1
SCHEMBL1009307 0.87 NPY5R (0.43) METAP2METAP1
SCHEMBL1008070 0.87 PTGDR2 (0.41) KMT2AALDH1A1METAP2METAP1
SCHEMBL1007921 0.87 NPBWR1 (0.44) L3MBTL1
SCHEMBL1008865 0.87 GCK (0.41) METAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK LPAR1 4693/4885LPAR5 4405/4885KMT2A 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.